Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Bejar

Showing results (11-20 of 103) with videos related to

Pageof 11
Sort By:
Haematologica|May 29, 2025
Broadening the differential diagnosis associated with germline <i>DDX41</i> mutationsRafael Bejar
Haematologica|June 2, 2014
Clinical and genetic predictors of prognosis in myelodysplastic syndromesRafael Bejar
NEJM Evidence|February 6, 2024
Can Lower-Risk MDS Achieve High Reward with Hypomethylating Agent Therapy?Rafael Bejar
Haematologica|December 11, 2013
What lies beyond del(5q) in myelodysplastic syndrome?Vera Adema, Rafael Bejar
Current Hematologic Malignancy Reports|August 28, 2017
Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDSAziz Nazha, Rafael Bejar
Blood|January 24, 2019
MDS overlap disorders and diagnostic boundariesTiffany N Tanaka, Rafael Bejar
Hematology/Oncology Clinics of North America|April 3, 2010
The genetic basis of myelodysplastic syndromesRafael Bejar, Benjamin L Ebert
Blood|September 20, 2014
Recent developments in myelodysplastic syndromesRafael Bejar, David P Steensma
Blood|November 23, 2013
The importance of subclonal genetic events in MDSRafael Bejar, Omar Abdel-Wahab
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related DisordersRafael Bejar, Peter L Greenberg
Pageof 11

Showing results (11-20 of 103) with videos related to

Sort By:
Pageof 11
Haematologica|May 29, 2025
Broadening the differential diagnosis associated with germline <i>DDX41</i> mutationsRafael Bejar
Haematologica|June 2, 2014
Clinical and genetic predictors of prognosis in myelodysplastic syndromesRafael Bejar
NEJM Evidence|February 6, 2024
Can Lower-Risk MDS Achieve High Reward with Hypomethylating Agent Therapy?Rafael Bejar
Haematologica|December 11, 2013
What lies beyond del(5q) in myelodysplastic syndrome?Vera Adema, Rafael Bejar
Current Hematologic Malignancy Reports|August 28, 2017
Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDSAziz Nazha, Rafael Bejar
Blood|January 24, 2019
MDS overlap disorders and diagnostic boundariesTiffany N Tanaka, Rafael Bejar
Hematology/Oncology Clinics of North America|April 3, 2010
The genetic basis of myelodysplastic syndromesRafael Bejar, Benjamin L Ebert
Blood|September 20, 2014
Recent developments in myelodysplastic syndromesRafael Bejar, David P Steensma
Blood|November 23, 2013
The importance of subclonal genetic events in MDSRafael Bejar, Omar Abdel-Wahab
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
The Impact of Somatic and Germline Mutations in Myelodysplastic Syndromes and Related DisordersRafael Bejar, Peter L Greenberg
Pageof 11